Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Dec 14, 2022 5:07pm

177 Views

Post# 35171891

RE:NASDAQ

They will be aware of this and they did say they will discusss both next fiscal years plans and the new dosing prototcol to shareholders via their calls with them and analysts. So it will be coming at some point. They've basically reaffirmed the sales guidance at that roughly +15% growth level, so they must be cranking away at the numbers. They'll get there, but sooner is definitely better.